Get started

Healthcarestocks

THYROCARE recently turned trend, about to test resistance zone.Hi. In this 1D chart I've plotted a few things: the recent MA 56 crossing that marked a trend turn, the approaching resistance zone from November last year and an interpretation of the movements since then as Elliott Waves. You can also see: There is still rooms for the Williams 224 to climb further. The historical volatility is lower than it was in November indicating a more stable trend. The Ichimoku is agreeing with the recent trend turn. There is possibility that the MACD will turn down across its signal but I believe that it will either skirt the signal and then continue rising or pass below it momentarily as the current Elliott Correction Wave plays out. It should be noted that the fundamentals of THYROCARE are absolutely excellent and therefore could be worth holding not only for the immediate future. Thank you. Please if you have any thoughts or comments do leave them below and I would gladly discuss or adjust my interpretations and methods. This does not constitute financial advice. Any prices, even if explicitly stated, are presented with intent to discuss the symbol and potential interpretations. Any trades shown or mentioned are examples and neither recommendations or mandates.
NSE:THYROCARELong
by Kabeldon
HEPA - a good buy opportunity? Very likely for me!First of all, I am not an expert when it comes to pharmaceutical companies! Why did I pick Hepion Pharmaceuticals (@hepionpharma)? 1. From a business perspective, they are healthy (Quick Ration of Assets vs. Liabilities is 9 to 1) 2. They came from a super high share price and are currently on a super low level 3. They are working on a product CRV431 (recently completed Phase 1 of 3) to tackle chronic liver disease and so far the results seem promising: Half a billion people worldwide are at risk unless new therapies are found. CRV431 is Hepion’s clinical phase, lead oral drug candidate for nonalcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease. CRV431 meets all of Hepion’s criteria for an effective and unique pleiotropic liver disease drug. Currently Phase 1 consists of three parts and the collective data from the Parts 1 and 2 demonstrate a favorable pharmacological, pharmacokinetic, and safety profile for CRV431. Part 3 data results are expected and with Phase 2 we might see bigger interest. Take a look at the chart and the health of the company with future prospective - then shape your own opinion. - This is no financial advice, so trade with care!- For transparency reasons: I am invested in $HEPA with 2/10 of my stock account size.
NASDAQ:HEPALong
by RedFoxTrading
MDT price target raised to 133; pent-up demand provides tailwindMDT price target was just upgraded to $133 by Citi. I see it overshooting that in the long run. Elective surgeries have been put off and doctor visits have been down throughout the pandemic so the amount of pent-up demand for surgical/medical care is going to be through the roof. With an aging population, healthcare is a MUST as a sector to allocate to. MDT is an excellent way to play this sector. After periods of consolidation, MDT looks ready to head towards it's price target. My guess is it hits $150 before it reaches any significant resistance. In terms of fundamentals, their current ratio is 2.1020, meaning they could pay their current liabilities 2 times over if sh*t hit the fan and business came to a complete halt. Highly unlikely, but if it did happen, you would be sheltered for a period of time.
NYSE:MDTLong
by EBITDAtiger
2
$SSY Announces $2 Million ExpansionSunlink Health Systems, Inc. Announces $2 Million Expansion, Capital and Operating Improvements at Trace Regional Hospital announced today that its wholly-owned subsidiary, Trace Regional Hospital, has implemented its Trace Forward Capital Plan totaling approximately $2 million to expand, upgrade and improve its physical plant, patient care, ancillary services and support areas. The Trace Forward Capital Plan includes an 8-bed expansion of its Pathways Care Program, a geriatric behavioral health service, which will bring Pathways to 26 total beds. "The expansion and upgrade of our Pathways Care Program will allow us to meet the growing demand for quality senior behavioral services as well as acute care hospital services in our northeast Mississippi service area." We wish to thank our elected Mississippi and Federal officials and staff for making these investments possible under various provisions of the CARES Act, which are funding a portion of the Trace Forward Capital Plan, and for prioritizing quality and access to care for the citizens of the Houston and Chickasaw County area during this uncertain and potentially disastrous period of the COVID-19 pandemic." finance.yahoo.com
AMEX:SSY
by AlenCiken
$CHEK Receives FDA IDE Approval for Pivotal Study of C-Scan®Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan® today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. The pivotal study will evaluate safety and performance of C-Scan as well as subject compliance with C-Scan. Now with IDE in hand, we aim to enter the last phase of demonstrating the clinical potential of C-Scan in the U.S., with the ultimate goal of commercialization in this important market. "We are in active discussions with a number of clinical sites as part of our preparations to begin the pivotal study in late 2021. finance.yahoo.com
NASDAQ:CHEK
by AlenCiken
Exela Technologies Wins $90 Million ContractExela Technologies Wins $90 Million Contract for Cloud-Hosted PCH Global, Delivering Healthcare Solutions for Major US Insurer $XELA today announced a 10 year, $90 million venture blending automation technologies, SaaS, and services through its PCH Global platform, which officially launched in September of last year. This effort will accelerate the digital transformation efforts for a major US health insurance company and is part of a broader relationship that included over $28 million in revenue in 2020. finance.yahoo.com
X
by AlenCiken
$ZOM could surge 100% due to upcoming launch of TruformaTangible catalyst behind surge is due to the upcoming launch of Truforma , Zomedica’s point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs. The platform will hit the market on March 30 , and ahead of the product’s debut, the company has also just nabbed a vital distribution deal. Last week, Zomedica announced an agreement with Miller Veterinary Supply who will distribute Truforma. Miller is the U.S.’s oldest wholesale veterinary distributor and one of the veterinary industry’s fastest growing businesses. The company will be Zomedica’s representative in the eastern and mid-eastern states. Its sales and customer service efforts will be bolstered by sales representatives assigned by Zomedica, which the company is currently recruiting as it prepares for the launch. The pet market has been a prime beneficiary of the pandemic’s stay-at-home mandates and according to the American Pet Products Association, spending in the segment reached a record $99 billion in the U.S. last year. Outlay on diagnostic care in this market is expected to grow to $2.8 billion in 2024 from $1.7 billion in 2019. H.C. Wainwright analyst Swayampakula Ramakanth says that ahead of Truforma’s debut, the agreement “strengthens the commercial machinery.” “We are encouraged by the progress in commercial preparation for the upcoming launch, and accordingly we are raising the probability of launch to 90%, up from 75% previously,” the 5-star analyst said. “Additionally, due to the lower yield of the long-term Treasury note that has resulted in a lower risk-free rate and a lower market risk premium, we have adjusted the discount rate to 6% from 12%.” To this end, Ramakanth boosted his price target on ZOM from $0.3 to $1.2, suggesting upside of an additional 20% from current levels. Needless to say, Ramakanth’s rating stays a Buy. finance.yahoo.com
AMEX:ZOM
by AlenCiken
23andMe to Merge with Virgin Group's VG Acquisition Corp. SPAC23andMe to Merge with Virgin Group's VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics. - 23andMe is a leading consumer genetics and research company that offers a personalized health and wellness experience, and has built a premier genetic database to unlock insights leading to the rapid discovery of promising new targets for drug development - Transaction will provide the capital to fund additional investment in key growth initiatives across 23andMe's consumer health and therapeutics businesses - The transaction will value the outstanding shares of capital stock of 23andMe at an aggregate enterprise value of approximately $3.5 billion - 23andMe CEO and Co-Founder Anne Wojcicki and Virgin Group's Sir Richard Branson are each investing $25 million into the $250 million PIPE and are joined by leading institutional investors including Fidelity Management & Research Company LLC, Altimeter Capital, Casdin Capital and Foresite Capital - The pro forma cash balance of the combined company will exceed $900 million at closing Completion of the transaction, estimated in the second calendar quarter of 2021. 23andMe is the only consumer genetic testing company with multiple FDA clearances for over-the-counter health and carrier status reports. 23andMe's existing equity holders will roll 100% of their equity into the combined company. Assuming no public shareholders of VG Acquisition Corp. exercise their redemption rights, 23andMe will be capitalized with up to $984 million in cash to fund operations and support new and existing growth initiatives. finance.yahoo.com
V
by AlenCiken
TDOC Breakout Trade, with Trigger and StopAfter the acquisition of LVGO, TDOC has traded sideways, creating a 6 month base. During that time TDOC has increased its institutional holders to 44 funds. Technically, the chart is showing an inverted head and shoulders base beakout, a trendline break, and consolidating below supply between 225-240. Above 240, TDOC can break upward to 300 with an upward target of 500. The chart is similar to ROKU's pre-breakout, which I also posted. (see related ideas). The stop would be a break below the downtrend, at 215.
NYSE:TDOCLong
by watchjoshtrade
2
MMED - Next Move? Psychedelic sector is starting to heat up once again A few micro-caps are leading the way by pushing towards previous ATH's & surging in volume: TRIP, CYBN, HOLL, MYCO MMED is reaching the end of its consolation box. We have 2 scenarios: - break down from the multi-month trend line - set daily lower lows - enter a new bearish cycle - break upper resistance at 4.30 - push towards ATH - continue the bullish trend and lead the push for psychedelic's Good Luck to All!
MLong
by LibraTradesNY
5
ATRA growth potentialAtara Biotherapeutics , Inc. (Nasdaq: ATRA ), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases "Atara made significant progress in 2020 and is well-positioned for a strong 2021," said Pascal Touchon, President and Chief Executive Officer of Atara. "As the most advanced allogeneic T-cell therapy company, nearing initiation and subsequent completion of a rolling BLA for our lead product candidate tab-cel®, we are making key investments in commercial infrastructure to ensure delivery of this potentially transformative therapy to patients in dire need. Atara also anticipates significant progress throughout 2021 on ATA188 for progressive MS with multiple data read-outs and, after recent productive interactions with the FDA, is poised to expand enrollment in the RCT and conduct an interim analysis in H1 2022."
NASDAQ:ATRALong
by tsvv
OUR VIEW ON JOB GEE GROUP INC #StockanalysisIN BUSINESS SINCE 1962, FUNDAMENTALLY, THE COMPANY SEEMS SOUND, SOURCING JOBS AND PROVING STAFFING IN THE AREAS OF HEALTHCARE, COMMERCIAL & PROFESSIONAL SERVICES. SEE MORE BELOW : GEE Group Inc. was incorporated in the State of Illinois in 1962, is a provider of specialized staffing solutions and is the successor to employment offices doing business since 1893. We operate in two industry segments, providing professional staffing services and solutions in the information technology, engineering, finance and accounting specialties and commercial staffing services through the names of General Employment, Access Data Consulting, Agile Resources, Ashley Ellis, Omni-One, Paladin Consulting and Triad. Additionally, the Company provides contract and direct hire professional staffing services through the following SNI brands: Accounting Now®, SNI Technology®, Legal Now®, SNI Financial®, Staffing Now®, SNI Energy®, and SNI Certes. Also, in the healthcare sector, through our Scribe Solutions brand, staff medical scribes who assist physicians in emergency departments of hospitals and in medical practices by providing required documentation for patient care in connection with electronic medical records. Technical Insider Own 9.20% Shs Outstand 17.75M Perf Week 30.84% Market Cap 24.96M Forward P/E - EPS next Y -0.51 Insider Trans -15.85% Shs Float 13.12M Perf Month 35.92% Income 10.10M PEG - EPS next Q -0.22 Inst Own 17.50% Short Float 0.06% Perf Quarter 38.48% Sales 129.80M P/S 0.19 EPS this Y 144.40% Inst Trans - Short Ratio 0.01 Perf Half Y 20.69% Book/sh 1.54 P/B 0.91 EPS next Y 32.90% ROA 8.20% Target Price 1.75 Perf Year 240.36% Cash/sh 0.79 P/C 1.77 EPS next 5Y - ROE 53.60% 52W Range 0.17 - 2.49 Perf YTD 40.63% Dividend - P/FCF - EPS past 5Y 20.90% ROI -2.20% 52W High -47.79% Beta 2.29 Dividend % - Quick Ratio 1.70 Sales past 5Y 24.50% Gross Margin 34.40% 52W Low 675.19% ATR 0.10 Employees 258 Current Ratio 1.70 Sales Q/Q -20.30% Oper. Margin -1.10% RSI (14) 68.16 Volatility 11.88% 8.79% Optionable No Debt/Eq 2.54 EPS Q/Q -147.00% Profit Margin 7.80% Rel Volume 3.12 Prev Close 1.40 Shortable Yes LT Debt/Eq 2.46 Earnings - Payout 0.00% Avg Volume 737.29K Price 1.30 Recom 2.00 SMA20 23.08% SMA50 26.89% SMA200 55.25% Volume 1,541,694 Change -7.14% The Content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained on our Site constitutes a solicitation, recommendation, endorsement, or offer by The Trading Regime Inc. or any third party service provider to buy or sell any securities or other financial instruments in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. The Trading Regime Inc. AMEX:JOB
AMEX:JOBLong
by EvaultFinancialGroup
PINC Swing Trade IdeaPremier, Inc. is a healthcare improvement company. The Company is uniting an alliance of approximately 4,000 United States hospitals and health systems and approximately 175,000 other providers and organizations to transform healthcare. The Company operates through two reportable business segments: Supply Chain Services and Performance Services. Its Supply Chain Services segment operates healthcare group purchasing organizations (GPO) and direct sourcing activities. The Company's performance Service segment provides integrated data and analytics, software as a service (SaaS) informatic products, consulting services, performance improvement collaborative, government services and insurance management services. The Company plays a role in the healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide.
NASDAQ:PINCLong
by Wiseinvest
Day Traders Lighting Up Reddit Spur Rally in ZomedicaDay Traders Lighting Up Reddit Spur Rally in Tiny Health Stock Zomedica Such outsized moves in small-caps are becoming par for the course these days. Surging at the open on the back of mentions in Reddit forums was Zomedica Corp., a company that develops medicines for pets. The stock jumped as much as 98% on Monday and is up almost four-fold from the start or the year. The penny stock garnered a mention in several Reddit forums over the past few days finance.yahoo.com
AMEX:ZOM
by AlenCiken
2
CAREPLS in the front seat from Glove SectorWEEKLY This week Carepls shown a very good reversal bull candle that respects the EMA50 weekly very well. We can also see that the candle actually broke the major downtrend that has been sliding for 4 months The Candle also is being fully supported by the volume candle, expecting carepls to at least run the bull for another week with couple of profit takings. Follow the TOP DragonHead and see a bigger picture Potential Earning : +-40% till the major resistance Good luck Trading *This is just education purposes, please do your own studies as this idea is not a buy sell call on any of the counter*
MYX:CAREPLSLong
by Cyrogx6
FTRP equilibrium watchFTRP is currently undergoing weekly consolidation (high, low, lower high, higher low, lower high...) As shown on the daily, the bullish engulfing candle looks great. However, there is strong resistance the top of this pennant/triangle/equilibrium whichever you name it. We would need to see some major surge in activity pick up here for a decisive break. *Be alert of potential false breakout* The scenario that would be ideal for bulls is one more pullback into the trading range to cool off the oscillators, before lift off. The tighter the range gets, the more explosive the move. Note how the resistance is the .786 fib - if we pull back I prefer to play the break of horizontal resistance rather than descending angles of a triangle - this is more reliable - the chart is showing you 3 upper wicks on daily candles at this area - sellers are distributing their stock here. In order to get on the move, the sellers must become exhausted enough to break through their distribution level. Taking a position on the break of the triangle at a lower level is feasible for those who want to load up more size for bigger gains - but don't lose sight of the .786 being major resistance and plan accordingly. An aggressive bull strategy when facing a pullback would be to play off the .618 or .5 fib levels from the swing high to low, and then add more on a clear break of the .786 to the upside (pyramiding) There are a few ways it can play out from there (back test some supports after break, run away etc) With this information come up with a plan for how you will handle various scenarios and where to take profits (previous high, fib extensions, measure move of the current structure) Disclaimer: This is NOT investment advice, I am not a financial advisor, do your own research. Adhere to proper risk management, position sizing, etc. Like and share this post if you found it informative, and please comment below - tell me what you think!
F
by Micro2Macro
Giant bullish flag or Descending Triangle for APHA.APHA is trading back into a Macro Bullish Flag or Descending Triangle drawn in dark blue, we have seen a fake-out to the downside where I have the blue human body icon, this is potentially forming an inverted H&S, and at the same time APHA is trading back into the Macro pattern, which started becoming bearish Jan 2018 during the hype before Canadian Rec. The KST wants to crossover bullishly, but is being rejected for the time being, you need to zoom in close to get a better view. Potential merit for a Ascending Triangle on the RSI.
A
by ScotianBot